ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing

ClearPoint Neuro, Inc.

2025-Q2 EPS reported -$0.42 vs consensus -$0.20 ▼ miss (-105.9%)

Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.
Operating expenses $11.2M (+16% YoY); gross margin 60% vs 63% on higher inventory reserves.
Entered $105M note financing with Oberland Capital; $30M funded at closing plus $3.5M stock purchase.
Cash and equivalents $41.5M at June 30, compared to $20.1M at year-end 2024.
Full-year 2025 revenue outlook reaffirmed at $36.0M-$41.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.